Moderna is revamping its digital team, eliminating 10% of roles under two digital departments, affecting about 50 employees, a person close to the matter told Fierce Pharma. The layoffs are ...

In 2024’s fourth quarter, Moderna’s cost of sales came out to $739 million, including $193 million in inventory write-downs and production wind-down costs of $259 million. In that latter ...

Moderna secures a multi-year agreement to supply its COVID-19 vaccine to 17 European countries, including Norway and North Macedonia. Vaccine formats include prefilled syringes, reducing ...

Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech that'll never recover its former glory -- which it built on the success of ...

Moderna's stock roared higher on the back of news about potential AI mRNA vaccines. The company also secured a supply contract in Europe. Shares of Moderna are down 90%, and the company has a huge ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other healthcare stocks. McKinsey reported that, since 2019, the US healthcare industry ...

Moderna, Inc. (NASDAQ:MRNA) today announced that it has been awarded a tender for the supply of its mRNA COVID-19 vaccine in the European Union (EU), Norway and North Macedonia. Under the ...

Moderna shares recovered from an early dip premarket despite the biotech's quarterly loss, as fading demand for its Covid-19 vaccine hurts sales. The company reported a net loss of $1.1 billion ...

Following four straight sessions of gains, Moderna (NASDAQ:MRNA) shares continued to trade higher in the premarket on Friday after the company received a tender to supply its COVID-19 vaccine in ...

Moderna missed earnings forecasts, posting a net loss of $1.1 billion, or $2.91 per share, 23% below the expectations of analysts polled by Visible Alpha. Revenue was 4% higher than forecasts ...

The American pharmaceutical company Moderna is developing an mRNA-based vaccine candidate for norovirus, designated as mRNA-1403. This vaccine is designed to protect against multiple norovirus ...

Sales at the once-high-flying biotech will likely continue to shrink for a while. But Moderna has a new cash cow in development, along with other potential winners. The U.S. government should ...